Dolutegravir

Rifabutin

No clinically significant interactions were observed.

No pharmaceutical opinion available for this interaction.

Mechanism

Dolutegravir

Pharmacodynamic effects

Recommendations

No dosage adjustment recommended.

Alternative solution(s)

Rifabutin

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HIV
Dose
Frequency
Duration (days)
AUC
Cmax
Cmin
Dolutegravir
2723
9
-
50 mg
QD
14
- 5%
+ 15%
- 30% *
Rifabutin
2723
9
-
300 mg
QD
14
 
 
 
Comment

Ref #2723 : * This decrease is unlikely to be clinically significant effect in integrase inhibitor-naive patients.

Reference
  • 2723
    Dooley K, Sayre P, Borland J, and al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor dolutegravir coadministered with rifabutin in healthy subjects . 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, April 16-18 2012. Abstract P-11.
  • 2868
    Dolutegravir (Tivicay), ViiV Healthcare, Quebec, Canada, 31 janv. 2020.
  • 2869
    Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan; 62(1): 21–27.
  • 3120
    Dolutégravir/abacavir/lamivudine (Triumeq), ViiV Healthcare, Québec, Canada, 31 janv. 2020.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Healthcare ULC, Quebec, Canada, 5 fév. 2020.
  • 3497
    Dolutegravir/Lamivudine (Dovato), ViiV Soins de santé ULC, Québec, Canada, 5 fév. 2020.